Global Dengue Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 and Forecast 2017-2023

05/feb/2018 08:30:54 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Dengue Vaccine Market: By Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, and Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, and Others), By End Users (Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs)) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 and Forecast 2017-2023

 Dengue Vaccine Market Report Description:

 Dengue vaccine market report gives a comprehensive outlook of dengue vaccine market across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, and Middle East & Africa (MEA) North America, and Europe. This report on dengue vaccine market gives historical, current, and future market sizes (US$ Mn) of product types, vaccine type, end users, and geographic regions. This report studies dengue vaccine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccine market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed dengue vaccine market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.


A sample of this report is available upon request @ 



Dengue vaccine market segmented on the basis of vaccine type and end-user


Based on vaccine type, dengue vaccine market is segmented into

·         Live- Attenuated Vaccines

·         Purified Inactivated Vaccines


Based on end-user, dengue vaccine market is segmented into

·         Hospitals

·         Clinics

·         Others


Dengue vaccine market is expected to grow at a significant rate during the forecast period. Market players are focusing on the development of dengue vaccines which are in different stages of development to grab the market share. For instance, TDEN PIV, a tetravalent purified inactivated vaccine for prevention of dengue, currently being developed jointly by alter Reed Army Institute of Research (WRAIR) and GSK in phase -1 clinical study. Similarly, TDV is a live attenuated vaccine that is being developed in phase-3 clinical trials by Takeda Pharmaceuticals. Furthermore, many research institutions such as Bhutantan Institute, Griffith University are involved in development of dengue vaccine. Government and non-government organizations initiating many programs and activities to increase vaccines usage and awareness among the people.


To view TOC of this report is available upon request @



Geographically dengue vaccine market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East &Africa. North America dengue vaccine market is expected to show significant growth rate owing to new vaccine launches and growing awareness and government initiatives to prevent the dengue. In September 2016, Sanofi launched dengvaxia in Mexico for prevention of dengue. Asia Pacific region dengue vaccine market expected to grow at a high rate due to increase in dengue coupled with an increase in government funding for dengue vaccination. In April 2016, The Philippines government initiated vaccination program for prevention of dengue. South East Asia and Western Pacific regions are more seriously affected by dengue.


 Need more information about this report @


Some of the market players in Dengue Vaccine Market include Sanofi (France), GlaxoSmithKline Plc (London), Takeda Pharmaceutical Company Ltd (Japan), Merck & Co Inc. (U.S.), Instituto Butantan (Brazil),  and VABIOTECH (Vietnam) to name a few.


Get access to full summary @

blog comments powered by Disqus è un servizio offerto da Factotum Srl